What does an Oxford mathematical biologist specialising in modelling cancer treatments do after completing their PhD? Why, go and do research at medical school, of course. Kit Gallagher, Schmidt Science Fellow at Harvard Medical School, is your man.

We present a new type of biomarker - based on a math equation rather than a genetic or transcriptomic assay. By capturing dynamic patterns in PSA during the first treatment cycle, we can predict prostate cancer outcomes across disease settings, paving the way for personalized treatment schedules.

JAMA Oncology@jamaoncology.com · 2mo ago

In patients with #ProstateCancer receiving #AdaptiveTherapy, mathematical biomarkers from first-cycle prostate-specific antigen (#PSA) dynamics predicted time to progression and overall survival better than standard PSA metrics. ja.ma/4wbDsyf

I'm excited to be starting at a Schmidt Science Fellow - I'll be applying my maths background in genomics to characterize the role of chromosomal instabilities in cancer evolution. Please reach out if you're interested in math modeling and quantitative tools for single-cell & longitudinal genomics!

Schmidt Science Fellows@schmidtfellows.bsky.social · 6mo ago

We are thrilled to introduce our 2026 Schmidt Science Fellows — thirty-two incredible scientists set to embark on the next step of their interdisciplinary journey with our support. schmidtsciencefellows.org/news/the-202... @schmidtsciences.bsky.social

Now time for @kitcgallagher.bsky.social on cool work with @mathonco.bsky.social on clinically applicable mathematical biomarkers using a Lotka-Volterra model #UKMathBio

Chasing Perfection - previous work to optimize adaptive therapy schedules for cancer rely on monitoring the patient continuously. We find that accounting for discrete clinical appointments across multiple tumor models motivates patient-specific personalization in optimal tx! doi.org/10.1101/2025...

Deriving Optimal Treatment Timing for Adaptive Therapy: Matching the Model to the Tumor Dynamics

Adaptive therapy (AT) protocols have been introduced to combat drug-resistance in cancer, and are characterized by breaks in maximum tolerated dose treatment (the current standard of care in most clin...

doi.org

Great news for the promotion and dissemination of open science, and hopefully institutions that benefit from this service will also be able to support this long-term initiative financially!

Richard Sever@richardsever.bsky.social · 2y ago

Big news: we are setting up a new non-profit organization to run bioRxiv and medRxiv. It's called openRxiv [no it's not a new preprint server; it's dedicated organization to oversee the servers] openrxiv.org 1/n

#HiSciSky! I'm in the final year of my PhD applying math modeling and deep learning to improve treatment scheduling in late-stage cancers. I'm starting to look for #postdocs in #mathonco and cancer #evolution if you know anyone who's hiring!

Sounds like what we need is something that makes it easier to generate quantitative, interpretable metrics that describe observable biological differences in tissue, without being a black box and requiring unreasonable amounts of training data... www.muspan.co.uk doi.org/10.1101/2024...

MuSpAn: A Toolbox for Multiscale Spatial Analysis

The generation of spatial data in biology has been transformed by multiplex imaging and spatial-omics technologies, such as single cell spatial transcriptomics. These approaches permit detailed mappin...

doi.org

Dave Barry@david-j-barry.bsky.social · 2y ago

Multiplex imaging presents a variety of challenges, but don't worry, AI will fix everything and you won't have to understand how any of it works! www.nature.com/articles/s41...